Prenatal surgical repair of myelomeningocele reduces the need for cerebrospinal fluid shunting and improves motor outcomes at 30 months compared with traditional postnatal repair.
Prenatal surgical repair of myelomeningocele, the most common form of spina bifida, reduces the need for cerebrospinal fluid shunting and improves motor outcomes at 30 months compared with traditional postnatal repair, according to the results of a recent randomized trial conducted at 3 maternal-fetal surgery centers in the United States. Researchers at Children's Hospital of Philadelphia, Pennsylvania, planned to include 200 patients, but the trial was stopped for efficacy after recruitment of 183 women. Results are based on 158 women whose children were evaluated at 1 year.
Only 68% of the infants whose myelomeningocele was repaired before 26 weeks of gestation, versus 98% of those in the postnatal repair group, died (fetal or neonatal) or required shunting by 1 year of age (relative risk [RR], 0.70; 97.7% confidence interval [CI], 0.58–0.84; P<0.001). Forty percent of the prenatal group and 82% of the postnatal group required shunting (RR, 0.48; 97.7% CI, 0.36–0.64; P<0.001). In addition, prenatal surgery resulted in an improved composite score for mental development and motor function at 30 months (P=0.007) and improved secondary outcomes, including hindbrain herniation by 12 months and ambulation by 30 months.
The downside is that prenatal surgery was associated with an increased risk for preterm birth and uterine dehiscence at delivery, compared with postnatal repair. One-third of the women who underwent prenatal surgery had an area of dehiscence or a very thin prenatal uterine scar at delivery. Fetuses treated prenatally were born at an average age of 34.1 weeks, with 13% delivered before 30 weeks' gestation; those in the postnatal repair group were born at an average of 37.3 weeks' gestation. None were delivered before 30 weeks.
Chemoattractants in fetal membranes enhance leukocyte migration near term pregnancy
November 22nd 2024A recent study highlights the release of chemoattractants from human fetal membranes at term, driving leukocyte activation and migration, with implications for labor and postpartum recovery.
Read More
Reproductive genetic carrier screening: A tool for reproductive decision-making
November 22nd 2024A new study highlights the efficacy of couple-based reproductive genetic carrier screening in improving reproductive decisions and outcomes, emphasizing its growing availability and acceptance among diverse populations.
Read More
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More